Immunosuppression medication and cardiac function improvement treatments might prevent Takayasu arteritis patients with aortitis from receiving cardiac surgery.

Author: Xiao-Min DAI ¹ ; Yu-Jiao WANG ¹ ; Zhen-Chun ZHANG ² ; Cheng-De YANG ³ ; Rui WU ⁴ ; Zhen-Yuan ZHOU ⁵ ; Xiao-Xiang CHEN ⁵ ; Xiao-Ning SUN ⁶ ; Chun-Sheng WANG ⁶ ; Li-Li MA ¹ ; Lin-Di JIANG ¹
Author Information

1. Department of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
2. Department of Rheumatology, Linyi People's Hospital, Linyi, Shandong 276003, China.
3. Department of Rheumatology, Ruijin Hospital, Shanghai Jiaotong University Medical College, Shanghai 200025, China.
4. Department of Rheumatology, The First Affiliated Hospital, Nanchang University, Nanchang, Jiangxi 330006, China.
5. Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University Medical College, Shanghai 200001, China.
6. Department of Cardiac Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Collective Name:and the East China Takayasu Arteritis (ECTA) Collaboration Group
Publication Type:Journal Article
MeSH: Aorta; Aortitis; Cardiac Surgical Procedures; Humans; Immunosuppression; Takayasu Arteritis/drug therapy*
From: Chinese Medical Journal 2020;134(5):625-627
CountryChina
Language:English